Loading...

9342-8530 Québec Inc.

DGCRF•PNK
Healthcare
Medical - Specialties
$0.00
$0.00(0.00%)

9342-8530 Québec Inc. (DGCRF) Stock Overview

Explore 9342-8530 Québec Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.7/100

Key Financials

Market Cap21.5K
P/E Ratio-0.00
EPS (TTM)$0.05
ROE-1.11%
Fundamental Analysis

AI Price Forecasts

1 Week$0.00
1 Month$0.00
3 Months$0.00
1 Year Target$0.00

DGCRF Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of 9342-8530 Québec Inc. (DGCRF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.00 and a market capitalization of 21.5K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for DGCRFStats details for DGCRF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for DGCRFAnalyst Recommendations details for DGCRF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

9342-8530 Québec Inc., a life sciences company, develops and commercializes products relating to the diagnosis of cancer in Canada. It focuses on molecular diagnostic tests for the detection and management of cancer. The company offers PCA3 test for the diagnosis of prostate cancer; and Guanylyl Cyclase C (GCC) marker and Previstage GCC colorectal cancer staging test for colorectal cancer patients, as well as PCP, a multi marker prostate cancer test. It also provides gene expression and copy number variation analysis, mutation detection, SNP genotyping, and platform and laboratory environmental services. The company was formerly known as DiagnoCure Inc. 9342-8530 Québec Inc. was founded in 1994 and is headquartered in Quebec, Canada.

CEO

Yves Fradet F.R.C.S.,

Employees

3

Headquarters

4535 Wilfrid-Hamel Boulevard

Founded

2009

Frequently Asked Questions

;